Antiretroviral News and Research

RSS

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

For more than a decade, researchers and advocates have marked HIV Vaccine Awareness Day with varying degrees of hope, cynicism and despair. This year, in large part because of the results of the Thai Prime-Boost vaccine study, there is greater cause for hope than ever before and a renewed sense of urgency to transform this hope into a reality.

18 May 2010

GHESKIO honored with 2010 Gates Award for Global Health

GHESKIO, an institution in Haiti founded nearly three decades ago to fight a mysterious killer disease later identified as AIDS, has been awarded the prestigious 2010 Gates Award for Global Health for its years of ground-breaking clinical service, research, and training to treat effectively and prevent the spread of the HIV/AIDS and other related illnesses, the Global Health Council announced today.

18 May 2010

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy (ART) interruption.

17 May 2010

HIV disease tends to progress at faster rate in infected individuals who consume more alcoholic drinks

HIV disease tends to progress at a faster rate in infected individuals who consume two or more alcoholic drinks a day, according to an important new paper in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc.

14 May 2010

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

In 1985 there was little hope for people with AIDS. Newspapers and television screens were filled with ghastly pictures of emaciated figures dying from a disease that had no cure.

13 May 2010

AHF targets BMS over pricing and policies for its HIV/AIDS drug

AIDS Healthcare Foundation will host a protest Wednesday morning, May 12th at 10:30am targeting New York-based Bristol Myers Squibb Co. over the pricing and policies for its key HIV/AIDS drug, Reyataz, one of the most expensive first-line AIDS treatment in the US, during the Bank of America-Merrill Lynch 2010 Health Care Conference.

13 May 2010

Avexa halts HIV drug trials

Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.

12 May 2010

Improving newborn care in first month of life essential for reducing child mortality

Improving newborn care in the first month of life is essential for reducing child deaths in developing countries, according to a global update on the Millennium Development Goals (MDGs) released today in the World Health Statistics 2010.

11 May 2010

Kaposi's Sarcoma-associated herpesvirus replicates, spreads by hijacking PYM cellular protein

Research from the University of Leeds has identified how the virus which causes Kaposi's Sarcoma replicates and spreads - opening a door to a possible new treatment for the disease.

7 May 2010

New CD4 test kit can improve quality of life for HIV and AIDS patients

The use of rapid point-of-care diagnostic tests for the measurement of CD4 T-cells, a marker of the immune system will be an important factor in improving the lives of people living with HIV and AIDS especially in developing and resource-poor countries.

7 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.

4 May 2010

PlusNews/IRIN examines HIV/AIDS elements of new adult mortality data

PlusNews/IRIN examines what the global adult mortality data, released Friday in the journal Lancet, suggests about HIV/AIDS. According to the news service, the study, based on an analysis of adult mortality rates between 1970 and 2010 in 187 countries, revealed: "HIV was key to reversing the worldwide decline in mortality from 1970 to 1990. Even though worldwide mortality is still about 26 percent lower than it was 40 years ago, there are regional imbalances.

3 May 2010

Study reveals wide disparities in global adult mortality rates

The most comprehensive assessment to date of global adult mortality appears today, April 30, in The Lancet . The study, "Worldwide mortality in men and women aged 15-59 years from 1970 to 2010: a systematic analysis", shows that across countries, inequality in adult mortality has grown to the point where adult men in Swaziland -- the country with the worst mortality rate -- now have a probability of premature death that is nine times the mortality rate of the best country, Cyprus.

3 May 2010

Cambodia closes 64.9 percent of illegal pharmacies

In a major crackdown, Cambodia has forced nearly 65 percent of illegal pharmacies operating in the country to close within the past five months. Led by an Inter-Ministerial Committee to Fight against Counterfeit & Substandard Medicines (IMC), the shops were targeted because of evidence that they were among the primary sources of substandard and counterfeit medicines in the country.

29 Apr 2010

Study examines lifestyle-related causes of death in AIDS patients

The study, by researchers from the University of Bristol and a large group of international collaborators, examined data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) which involved nearly 40,000 patients who started ART between 1996 and 2006 in Europe and North America.

29 Apr 2010

Causes of death in AIDS patients

New research shows that Antiretroviral Therapy (ART) continues to dramatically reduce rates of mortality from HIV infection in high-income countries, such that non-AIDS-related deaths exceed AIDS deaths after approximately four years of taking ART.

28 Apr 2010

Report looks at AIDS funding in developing countries

"A global pullback on commitments to fund and fight AIDS is resulting in restrictions on the number of people being enrolled into treatment programmes, more frequent drug shortages, and reduced national AIDS budgets," according to a report released Monday by the International Treatment Preparedness Coalition, BMJ News reports.

28 Apr 2010

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.

27 Apr 2010

Research documents early warning signs resulting from global pullback on AIDS funding

Rationing Funds, Risking Lives: World Backtracks on HIV Treatment, the new report from the International Treatment Preparedness Coalition, documents early warning signs resulting from the global pullback on AIDS commitment and funding: caps on the number of people enrolled in treatment programs, more frequent drug stock outs, and national AIDS budgets falling short.

26 Apr 2010